ChemoCentryx, Inc.
CCXI announced today preclinical results for CCX872, the Company's
next-generation, orally bioavailable inhibitor of the chemokine receptor known
as CCR2. The findings showed that treatment with CCX872 improved multiple
parameters of renal function in an in vivo model of diabetic nephropathy. The
data were reported in an oral presentation titled, "CCR2 Inhibition Improves
Renal Function in Diabetic BTBR ob/ob Mice," at the 48th Annual Meeting of the
European Association for the Study of Diabetes (EASD) taking place in Berlin.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in